Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138889 · ClinicalTrials.gov registry record · Phase 1
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
NCT03138889 is a Phase 1 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 162 participants.
The verdict
NCT03138889, a Phase 1 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
Study Summary
This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without chemotherapy. The study is comprised of two groups; dose optimization and dose expansion cohorts. Dose Optimization included first-line and second-line advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) The dose expansion cohort will include first-line NSCLC patients.
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- DRUG NKTR-214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2017-06-09 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138889
The ClinicalTrials.gov registry entry for NCT03138889 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03138889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138889 about?
NCT03138889 is a clinical study titled "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors". This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without chemotherapy. The study is comprised of two groups; dose optimization and dose expansion cohorts. Dose Optimization included ...
What is the current status of trial NCT03138889?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2017-06-09. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT03138889?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), NKTR-214 (DRUG).
Who is sponsoring clinical trial NCT03138889?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.